Investors
2021 Equity fundraising
Since its inception, BioFilm Technologies shareholders have invested 12M€.
The 2021 Equity fundraising is the first equity round open to new investors.
BioFilm Control aims to raise €6 million Equity to finance a multi-centric clinical study and obtain Social Security reimbursement in France and Germany.
BioFilm Pharma aims to raise €6 million Seed Equity, to finance a PreClinical development on a hit olecule for wound infections, to prepare a Phase 1 Clinical Trial in mid 2024.
Milestones
BioFilm Control milestones
(Q1 2021) CE Marking for Infected Wounds and Social Security reimbursment application, base on clinical trial results.
(Q1 2022) Multicentric Clinical Study 150 patients France + Germany
BioFilm Pharma milestones
(Q4 2020) Mode of action results on one to three Hit Molecules
(2nd semester 2023) Preparation of 20M€ Serie A equity round for Phase I / Phase II Clinical Trial
Risk Assessment
As far as risk assessment is concerned, the BioFilm Technologies project is quite specific:
1) BioFilm Technologies conducts two main businesses : Diagnostics with short term go-to-market, and Drugs with high profit potential
The Diagnostics business line is close to go-to-market (Q3 2022), providing clear visibility on cash need and profitabilty milestones.
The Drugs business lines has high R&D expenses, which will be triggered upon achievement of further financing operations without jeopardizing the Diagnostics business branch.
2) Our technology and know-how enable us to identify multiple drugs for bacterial applications
With appropriate financing, a “Monte Carlo” model used in the valuation study shows that the number of applications we intend to develop is big enough to have a statistical “close-to-certainty” that at least one of them will reach the market.
3) The underlying technology is already proven and operational
Our technology is already operational for diagnostics in several leading hospitals in Europe (clinical trial mode and compassionate mode), and our drug development branch, after only 18 months of existence, has already generated the discovery of remarkable molecules
4) BioFilm Pharma has already discovered molecules with a high potential
Thanks to our technology, we will screen molecules and discover new hits for other applications
5) We give priority to drug developments with lowest risks
2 main factors significantly reduce the risks of our current drug developments, as compared to other biotech projects :
We currently select only simple molecules, that have already been tested on man for other applications (limited toxicity risk)
We have started with skin-applicated drugs (topical) which limits the toxicity risks on humans and will speed up the testing phases.
6) Biotech are often seen as high yield but risky investments. However, grant easing significantely decreases the risk.
Investing in a United Nations Sustainable Development Goal has financial benefits as these areas benefit from many non-dilutive grants and subsidies
The early stages of development showed a ratio close to €1 of grants for €1 of equity.
7) This impact investment is not correlated with market fluctuations
Bacteria are not sensitive to the stock market.
Financial markets, however, may be sensitive to bacteria, in the sense that when a particularly resistant disease begins to spread, accompanied by media hype, the valuations of the credible solution providers will skyrocket.